Steinert, H C (2011). PET and PET-CT of lung cancer. In: Juweid, M E; Hoekstra, O S. Positron Emission Tomography. New York [etc.]: Humana Press, 33-51.
Full text not available from this repository.
View at publisher
Accurate staging is essential to offer the patient the most effective available treatment and the best estimate of prognosis. In non-small cell lung cancer (NSCLC), surgical resection offers the best chance of cure in the early stages, either alone or in combination with chemo- or radiotherapy at the more advanced stages. However, many patients present with metastatic disease at the time of diagnosis. Both computed tomography (CT) and positron emission tomography (PET) using fluorodeoxyglucose (FDG) play an important role in the diagnosis and staging of lung cancer. CT provides excellent morphologic information but has significant limitations in differentiating between benign and malignant lesions either in an organ or in lymph nodes. FDG-PET is highly accurate in the detection of mediastinal lymph node metastases as well as extratharacic metastases. However, due to the poor anatomic information provided by PET, additional morphologic information is needed to properly locate a lesion. Imaging with PET integrated with computed tomography (PET/CT) offers essential advantages in comparison to PET alone, CT alone, or visual correlation of separate PET and CT. A combined PET/CT system provides PET and CT images perfectly coregistered so that lesions can be exactly localized.
|Item Type:||Book Section, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Nuclear Medicine|
|Dewey Decimal Classification:||610 Medicine & health|
|Date:||11 May 2011|
|Deposited On:||05 Mar 2012 08:50|
|Last Modified:||05 Apr 2016 15:31|
|Series Name:||Methods in Molecular Biology|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page